Premium
Global private equity funds, including Bain Capital, KKR, and Advent International, are in talks for a controlling stake in Sai Life Sciences at a valuation of $600-700 million, three people aware of the development said. Sai Life Sciences (SLS) is a Hyderabad-based pharmaceutical contract research and development, and manufacturing (CRDMO) ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.